Andrew Kay
Scientific Advisory Board
Andrew Kay, BPharm Hons has extensive board and international business experience both in Pharmaceutical Biotech and major Pharmaceutical companies. Chairman CaNDy Therapeutics, NeRRe Therapeutics, and Blueberry Therapeutics, Senior Advisor HealthCap VC. Previously CEO and board member of Algeta (top 25 biotech, oncology, market cap $2.9 Billion) with R&D/manufacturing in Europe and co-promotion in the USA. Previous Chairman of Wilson Therapeutics (successfull $855Mn exit). Kay’s previous roles include Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis, and several other senior commercial positions in Europe and the USA with AstraZeneca, Eli Lilly, Sandoz and Boots. International career spans CEO, country/ business management, marketing, sales, medical/regulatory, manufacturing. Assignments include roles in the USA, UK, Italy, Switzerland and Scandinavia. Wide range of major licensing deals and product launch experience covering the major therapeutic areas and 8 blockbuster launches.
Wide range of major licensing deals and product launch experience covering the major therapeutic areas and 8 blockbuster launches.
Gregory Gores
Scientific Advisory Board
Professor, Executive Dean for Research across the Mayo enterprise Gregory J. Gores, MD, is a senior academician with broad contributions to research, clinical practice, education and leadership. His research contributions include sustained federal funding for more than 25 years, over 500 publications, an H-index of 103 and over 30,000 citations. Based on these accomplishments, he was appointed as a Distinguished Mayo Investigator. His clinical focus on cholangiocarcinoma and hepatobiliary neoplasia has led to pioneering work employing novel protocols for cholangiocarcinoma combined with liver transplantation. His leadership positions include past presidency of the American Association for the Study of Liver Disease and the International Liver Cancer Association. He is a current member of the American Gastroenterological Association Governing Board. He has also served as chair of the Gastroenterology and Hepatology Division at Mayo Clinic Rochester, medical director of the Liver Transplant Program.
Jesper B. Andersen
Scientific Advisory Board
Associate Professor, MSc PhD Affiliation Jesper B. Andersen is a lead cancer researcher in the field of translational medicine with 12 years of experience working in the United States. He has published more than 80 seminal research papers in the field of the molecular pathogenesis of Hepato-Pancreato-Biliary (HPB) cancers. In 2014, he established the Andersen group at Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Department of Health and Medical Sciences at University of Copenhagen, Denmark.
The Andersen group is focusing on understanding the molecular tumor heterogeneity, how genome alterations are involved in drug resistance and patient stratification as well as utilizing disease models for testing new therapies. He is the co-founder of the European Network for the Study of Cholangiocarcinoma (ENSCCA), member of the management committee for the EU COST Action ”European Cholangiocarcinoma Network”, member of the International Cholangiocarcinoma Research Network (ICRN) under the US Cholangiocarcinoma Foundation, and part of the steering committee in the Global Cholangiocarcinoma Alliance (GSA).
Jo Klaveness
Scientific Advisory Board / Research Partner
MSc Pharm., University of Oslo, PhD, Professor emeritus Jo Klaveness is a professor of medical chemistry at the University of Oslo’s School of Pharmacy and the founder of Drug Discovery Laboratory AS. He has a doctoral degree and a master’s degree in organic chemistry as well as an MSc Pharm. in pharmaceutical chemistry from the University of Oslo. He has held several positions in Nycomed, including as project manager and Vice President of the R&D organisation, and served in several boards of directors, including for Pronova Biopharma ASA and Omegatri AS. Klaveness is the inventor of more than 160 patent families related to several pharmaceutical products and other products that are on the market.